Navigation Links
Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
Date:8/4/2008

EMERYVILLE, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective drugs in the areas of women's health and cancer, announced today that Tom Chesterman, SVP and CFO of Bionovo, will be presenting at the BMO Capital Markets 2008 Focus on Healthcare Conference in New York. The presentation is scheduled to begin at 2:15 PM ET on Tuesday, August 5, 2008 at the Millennium Broadway Hotel in New York.

The presentation will be webcast and can be viewed on Bionovo's website at http://webcasts.bionovo.com. A replay of the webcast will become available approximately 24 hours after the presentation ends and will continue to be accessible for twelve months after the event via Bionovo's website.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol BNVI. For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... WESTLAKE VILLAGE, Calif. , March 24, 2017 /PRNewswire/ ... medical dermatology and aesthetics company, today announced that ... Financial Officer, effective March 24.   Peterson, who ... will succeed John Smither , who is retiring ... serve Sienna in an advisory capacity. Peterson joins Sienna ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake ... and elastic characteristics when deformed, which is identical to how the human discs ... compressive forces and return to its natural state along a hysteresis curve, exactly ...
(Date:3/23/2017)... Research and Markets has announced the ... to their offering. ... The Global Market for Bioproducts Should Reach ... a CAGR of 8.9%, This research report ... seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and ...
(Date:3/23/2017)... Mass. , March 23, 2017 /PRNewswire/ ... partner to global in vitro diagnostics manufacturers ... of the industry,s first multiplexed Inherited ... disease testing by next-generation sequencing (NGS). The ... were developed with input from industry experts ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Who risk to be deprived ... the full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE ... FIELD? Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:3/1/2017)... -- Aware, Inc. (NASDAQ: AWRE), a leading supplier of biometrics ... has resigned, effective March 3, 2017, as co-Chief ... Treasurer of Aware citing a desire to retire.  Mr. ... the Board of Directors of Aware. ... co-President, General Counsel has been named Chief Executive Officer, ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
Breaking Biology News(10 mins):